Skip to main content
TipRanks
Go Ultimate75% OFF

Evolus (0K16) AI Stock Analysis

0 Followers
GB:0K16

Evolus

(LSE:0K16)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue Growth and EBITDASustained double-digit revenue growth alongside four consecutive quarters of positive adjusted EBITDA indicates improving operating leverage and commercial traction. This combination strengthens the path toward self-funded expansion, although continued execution is needed to convert growth into durable GAAP profitability.
Negative Factors
Negative Equity and LeverageNegative stockholders’ equity and substantial debt reduce financial flexibility and leave the company more exposed if operating improvement slows. The capital structure may require refinancing or additional capital, creating dilution and execution risk while profitability remains unproven.

Evolus (0K16) vs. iShares MSCI United Kingdom ETF (EWC)

0%5%10%15%20%25%GB:0K160.00%EWC+8.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$431.55M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-13.9
Beta (1Y)
1.67
Revenue Growth
13.87%
EPS Growth
48.13%
Country
UK
Employees
353
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Evolus Business Overview & Revenue Model

Company Description

Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified...

Evolus Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Mar 09, 2027
Earnings Call SentimentPositive

The call was strongly positive, supported by 13% third-quarter revenue growth, double-digit global toxin growth, more than 40% Evolysse growth, expanding customer and consumer engagement, four consecutive quarters of positive adjusted EBITDA, lower operating expense guidance, and reaffirmed 2028 financial targets. The main challenges were softer consumer confidence, a regulatory untitled letter, seasonally lower third-quarter purchasing volumes, higher planned fourth-quarter expenses, a lower cash balance, and the absence of Sculpt revenue in 2026. Highlights significantly outweighed the lowlights.

Positive Updates

Revenue Growth and Positive Adjusted EBITDA
Third-quarter revenue was $78 million, up 13% year-over-year, including $70.1 million of global toxin revenue and $7.9 million from injectable HA gels. Through the first nine months, revenue was $235.2 million, up 14% year-over-year. Adjusted EBITDA was positive for the fourth consecutive quarter at $1.2 million, a $4.2 million improvement versus the prior-year quarter, and reached $6.4 million through the first nine months compared with a loss of $16.5 million a year ago.

Negative Updates

Softer Consumer Confidence
Management noted that consumers continue to prioritize beauty and appearance despite softer consumer confidence.

Company Guidance

Evolus continues to expect full year revenue between $330 million and $337 million, representing 11% to 13% growth over 2025, with the annual outlook implying a sequential increase in the fourth quarter; full year adjusted gross profit margin remains 67% to 67.5%, while full year non-GAAP operating expenses are expected to be between $210 million and $213 million, from the prior range of $212 million to $216 million, representing approximately flat to 2% growth over 2025, and full year adjusted EBITDA margin remains low to mid-single-digit. Evolysse and Estyme injectable HA gels are expected to contribute 10% to 12% of full year revenue, with no revenue contribution from Evolysse Sculpt in 2026; Evolysse Sculpt approval is anticipated in the fourth quarter of 2026 and launch in 2027, Lips submission is expected before the year-end with launch in early 2028, Profhilo approval is anticipated around 2030, and 2028 targets remain annual revenue of $450 million to $500 million and adjusted EBITDA margins of 13% to 15%.

Evolus Risk Analysis

Evolus disclosed 52 risk factors in its most recent earnings report. Evolus reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks
1.We have incurred significant losses since our inception, and we may continue to incur losses, which could adversely affect the market price of our common stock and our ability to raise additional capital.Q3, 2026
2.Any failure or refusal by our licensors or any other third party to supply our products that we may develop could delay, prevent or impair our clinical development or commercialization efforts.Q3, 2026

Evolus Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0K16 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
DERMDERM49Neutral$100.22M-17.75-16.07%―17.03%49.40%
SNOASNOA43Neutral$4.10M-0.79-36.40%―38.69%58.68%
ORGOORGO42Neutral$102.44M-0.65-46.25%―-24.33%-1171.44%

* Healthcare Sector Average

Performance Comparison

-75%-50%-25%0%GB:0K16SNOAORGODERMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0K16 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0K16Evolus, Inc.14.580.000.00%
SNOASonoma Pharmaceuticals, Inc.0.72-2.49-77.51%
ORGOOrganogenesis Holdings0.77-4.62-85.70%
DERMJourney Medical Corporation3.30-4.28-56.46%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.